Volume 23 Issue 4

Reviews Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma

Edward Wolfgang Lee, Sarah Khan

Clin Mol Hepatol. 2017;23(4):265-272.

Treatment options after sorafenib failure in patients with hepatocellular carcinoma

Imane El Dika, Ghassan K. Abou-Alfa

Clin Mol Hepatol. 2017;23(4):273-279.

Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 – a review of important differences compared to the CT/MRI system

Tae Kyoung Kim, Seung Yeon Noh, Stephanie R Wilson, Yuko Kono, Fabio Piscaglia, Hyun-Jung Jang, Andrej Lyshchik, Christoph F. Dietrich, Juergen K. Willmann, Alexander Vezeridis, Claude B Sirlin

Clin Mol Hepatol. 2017;23(4):280-289.

Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification

Dong Ho Lee

Clin Mol Hepatol. 2017;23(4):290-301.

Histopathological evaluation of liver fibrosis and cirrhosis regression

Regina C. Lo, Haeryoung Kim

Clin Mol Hepatol. 2017;23(4):302-307.

Editorials Use of sofosbuvir in chronic kidney disease: Is it necessary?

Tae Seop Lim, Sang Hoon Ahn

Clin Mol Hepatol. 2017;23(4):308-310.

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?

Joon Yeul Nam, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(4):311-313.

Lamivudine: fading into the mists of time

Jonggi Choi, Young-Suk Lim

Clin Mol Hepatol. 2017;23(4):314-315.

Original Articles Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function

Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique

Clin Mol Hepatol. 2017;23(4):316-322.

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience

Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim

Clin Mol Hepatol. 2017;23(4):323-330.

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B

Kwan Sik Lee, Young-Oh Kweon, Soon-Ho Um, Byung-Ho Kim, Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon-Ju Lee, Dong Joon Kim, Tae Hun Kim, Young-Sok Lee, Kwan Soo Byun, Daeghon Kim, Myung Seok Lee, Kyungha Yu, Dong Jin Suh

Clin Mol Hepatol. 2017;23(4):331-339.

Case Report Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review

Tae Suk Kim, Ji Hoon Kim, Baek hui Kim, Young-Sun Lee, Yang Jae Yoo, Seong Hee Kang, Sang-June Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun

Clin Mol Hepatol. 2017;23(4):340-346.